Furthermore, 2 risk groups of patients with lung cancer, characterized by different prognoses and immune landscapes, were stratified using a risk scoring model that comprised 3 AS-related genes (CD52, FABP5, and FCGR3A). This evidence concerns the gene FCGR3A and lung carcinoma.